ABI-009 (Nab-sirolimus) in Patients With Genetically-confirmed Leigh or Leigh-like Syndrome
Status:
Not yet recruiting
Trial end date:
2025-03-31
Target enrollment:
Participant gender:
Summary
A phase 2a, open-label study to evaluate the safety, tolerability, and clinical activity of
ABI-009 (nab-sirolimus) in patients with genetically-confirmed Leigh or Leigh-like syndrome